This paper outlines our vision for empowering patients, demonstrating how a CDMO can play a pivotal role in the advancement of patient-friendly drug delivery systems. We highlight the importance of flexibility and adaptability in manufacturing processes, illustrating how these qualities are essential for bringing innovative solutions to life.

This white paper will explore the value of this “right-now” capability and how developments in causal AI are making it possible in a fast-moving, data-driven universe of tools and technologies. Download now.

This whitepaper examines how adaptive clinical trial designs in oncology can improve patient outcomes and treatment efficacy through real-time modifications, while also highlighting the regulatory and ethical challenges these designs pose within IRB frameworks. 

We interviewed 24 Medical Affairs leaders on the critical success factors for building a Best Practice Medical Affairs organization. This report shares what we learned.

Learn how speed and accuracy of clinical information is transforming healthcare delivery and how your brand can become part of these high-value clinical conversations at the point of decision-making. Download now.

Typical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic.

To improve market access, companies need to ensure that needed treatments reach the right patients at the right times and at affordable prices. To accomplish this optimal market access, companies must work closely with payer organizations, which typically control over which drugs are embraced by providers and their patients. This paper describes how companies can leverage real world data to support market access strategies such as: identifying the right payers for pilot programs, understanding payer preferences for specific drug classes or treatment pathways, and more. Download now. 

Is your clinical trial data at risk? Discover how Imaging Core Labs and Endpoint Adjudication Committees (EAC) can safeguard your data quality and accuracy. Our whitepaper exposes the hidden dangers and offers solutions to avoid costly delays and errors.

We interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned.

As AI reshapes drug discovery and R&D, shifting value contributions may impact historical tax positions and introduce new audit risks. Download now to stay ahead of regulatory challenges.